Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Thyroid Cancer

Clinical and regulatory intelligence for Thyroid Cancer with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 0
Assets: 4

Relevant assets

Thyroglobulin →

Relevant companies

Recent signals(9)

ClinicalAugust 8, 2026

New PET Imaging Test for Thyroid Cancer Shows Potential for Improved Radioactive Iodine Uptake Prediction

A study is evaluating a new PET imaging test using 18F-TFB to predict radioactive iodine uptake in thyroid cancer patients.

ClinicalJuly 29, 2026

Thyroglobulin Antibody Positivity Linked to Delayed Absorption Post-Microwave Ablation in PTC

Preoperative thyroglobulin antibody positivity is associated with delayed absorption after microwave ablation for papillary thyroid carcinoma.

ClinicalJuly 22, 2026

Phase 2 Study on 124-I-PET/CT Dosimetry in High-Risk Differentiated Thyroid Cancer

A phase 2 pilot study is comparing 124 I-PET/CT dosimetry methods in patients with high-risk differentiated thyroid cancer.

ClinicalJuly 18, 2026

Mayo Clinic Trial on Health Coaching for Thyroid Cancer Survivors

A clinical trial is evaluating the effectiveness of health and wellness coaching on treatment adherence in thyroid cancer survivors.

ClinicalJuly 12, 2026

Study on Predictors of Recurrence in Papillary Thyroid Carcinoma Initiated

An observational study aims to identify factors associated with recurrence in papillary thyroid carcinoma post-treatment.

ClinicalJuly 12, 2026

Single-cell analysis reveals immune evasion pathways in thyroid cancer metastasis

This study identifies LAG3 and TIGIT as critical immune checkpoints in thyroid cancer, challenging the efficacy of PD-1 blockade.

ClinicalJuly 7, 2026

Thyroid cancer exosomal SPP1 drives macrophage M2 polarization and tumor progression

Thyroid cancer-derived exosomal SPP1 promotes macrophage M2 polarization, contributing to tumor progression.

ClinicalJuly 5, 2026

Study on Incidental Thyroid Cancer in Autoimmune Thyroiditis Patients Launched

A new clinical trial has been initiated to evaluate the incidence of thyroid cancer in patients with autoimmune thyroiditis.

ClinicalJune 29, 2026

Lenvatinib Evaluated for Invasive Thyroid Cancer Surgery Outcomes

A study is underway to assess the safety and efficacy of neoadjuvant lenvatinib in patients with invasive differentiated thyroid cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Thyroid Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.